Akero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials

Reuters11-07

<a href="https://laohu8.com/S/AKRO">Akero Therapeutics</a> Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials

Akero Therapeutics Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), including those with compensated cirrhosis (F4c) and pre-cirrhotic stages (F2-F3). The results, which corroborate previously reported antifibrotic effects and indicate the potential to reduce risk of disease progression in MASH, will be presented at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, D.C. The data include post-hoc analyses from the 96-week SYMMETRY trial and digital pathology findings from the HARMONY trial, both supporting fibrosis improvements associated with efruxifermin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571105-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581024020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581024020","market":"fut","top_or_hot":-1,"title":"Akero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), including those with compensated cirrhosis (F4c) and pre-cirrhotic stages (F2-F3). The results, which corroborate previously reported antifibrotic effects and indicate the potential to reduce risk of disease progression in MASH, will be presented at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, D.C. The data include post-hoc analyses from the 96-week SYMMETRY trial and digital pathology findings from the HARMONY trial, both supporting fibrosis improvements associated with efruxifermin.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571105-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), including those with compensated cirrhosis (F4c) and pre-cirrhotic stages (F2-F3). The results, which corroborate previously reported antifibrotic effects and indicate the potential to reduce risk of disease progression in MASH, will be presented at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, D.C. The data include post-hoc analyses from the 96-week SYMMETRY trial and digital pathology findings from the HARMONY trial, both supporting fibrosis improvements associated with efruxifermin.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571105-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL9Q1f8w:1","article_id":"2581024020","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581024020","pubTimestamp":1762516819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akero Therapeutics Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis , including those with compensated cirrhosis  and pre-cirrhotic stages . The results, which corroborate previously reported antifibrotic effects and indicate the potential to reduce risk of disease progression in MASH, will be presented at the 76th Annual American Association for the Study of Liver Diseases  The Liver Meeting 2025, scheduled for November 7-11, 2025, in Washington, D.C. The data include post-hoc analyses from the 96-week SYMMETRY trial and digital pathology findings from the HARMONY trial, both supporting fibrosis improvements associated with efruxifermin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4505":"高瓴资本持仓","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","AKRO":"Akero Therapeutics","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Akero Therapeutics报告Efruxifermin在96周MASH试验中显示出抗纤维化活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":0.9,"NDAQ":0.9},"content_text":"Akero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials\n    \n\n        Akero Therapeutics Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), including those with compensated cirrhosis (F4c) and pre-cirrhotic stages (F2-F3). The results, which corroborate previously reported antifibrotic effects and indicate the potential to reduce risk of disease progression in MASH, will be presented at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, D.C. The data include post-hoc analyses from the 96-week SYMMETRY trial and digital pathology findings from the HARMONY trial, both supporting fibrosis improvements associated with efruxifermin.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571105-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581024020","isCrawlerRequest":true}